Introduction
Solid tumors require for their growth the formation of a vascular system, 1 which can arise from the sprouting of preexisting vessels or from the recruitment of endothelial progenitor cells. 2 Angiogenesis depends on a balance between endogenous stimulators and inhibitors. Proangiogenic factors such as vascular endothelial growth factor are produced by tumor and/or stromal cells, whereas inhibitory factors are derived from extracellular matrix and basement membrane proteins. [3] [4] [5] Angiogenesis and tumor progression can be controlled by molecules that able to inhibit the activity of proangiogenic factors, 4 or alternatively, by molecules possessing direct anti-angiogenic activities. In this latter case, systemic administration of plasminogen-derived fragments such as angiostatin K1-5 effectively suppressed tumor growth in different murine models. 6, 7 Anti-angiogenic therapy requires prolonged maintenance of therapeutic levels in vivo to achieve tumor regression. Because bolus injections of anti-angiogenic factors are rapidly cleared from the blood, 8 cost-effective repeated injection of recombinant proteins are needed. Recombinant vectors constitute an efficient alternative to protein production and delivery. Thus, a recombinant adenovirus (Ad) encoding angiostatin K1-3 (AdK1-3) induced a significant arrest of glioma and breast carcinoma growth after intratumoral delivery. 9 Moreover, intratumoral injection of AdK1-5 but not AdK1-3 led to significant regression of mammary carcinoma. 7 Finally, systemic delivery of AdK1-5 in mice more efficiently inhibited lung invasion by melanoma and mammary carcinoma establishment than did AdK1-3. 7 The best efficiency of angiostatin K1-5 was because of an essential role of kringle 5 in endothelial cell growth inhibition. 5 Adenoviruses produce high levels of angiostatic molecules when delivered intravenously with only a small portion able to reach tumor sites. Moreover, high circulating levels of these molecules could lead to a risk of toxicity as observed for endostatin 10 or vascular endothelial growth factor inhibitors. 11, 12 To improve this therapeutic approach and minimize side effects, Ad-encoding angiostatic factors could be injected intratumorally. In this case, their efficiency would be dependent on their ability to transduce tumor cells. Ad5-derived vector entry depends on the binding of capsid fiber protein to the coxsackie virus and Ad receptor (CAR), 13, 14 followed by endocytosis after penton-base interaction with integrins. 13, 14 However, CAR is expressed at low levels in many tumor cells [15] [16] [17] [18] and often downmodulated in accordance with its tumor inhibitor function. 19, 20 Several approaches have been developed to provide Ad with new entry pathways into tumor cells. 21 One strategy relies on genetic incorporation of peptides presenting a high affinity for tumor receptors into Adcapsid proteins. For example, insertion into fiber protein of an RGD peptide able to bind avb3/avb5 integrins provided Ad with the ability to more efficiently transduce tumor cells in vitro, [22] [23] [24] but also enhanced tumor infectivity in vivo. [25] [26] [27] Also, insertion into fiber protein of a polylysine peptide able to bind heparan sulfate glycosaminoglycans allowed Ad to better transduce human umbilical vascular endothelial cells (HUVECs) in vitro 28 and ovarian cancer cells in vivo.
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In this study, we examined the ability of an NGR motif inserted into different capsid proteins to provide Ad with a new entry pathway into tumors. For the first time, a very efficient entry pathway into endothelial cells and tumor cells was obtained by inserting an NGR peptide into the hexon protein. Moreover, we provided evidence that NGR-bearing Ads enhance the potential of an antiangiogenic therapy.
Results

Construction and production of capsid-modified Ad
To provide Ad with a new entry pathway into CARnegative cells, we introduced a previously described NGR-containing peptide 30 into either fiber (AdFNGR) or hexon (AdHNGR) capsid-proteins of a lacZ-recombinant Ad (Table 1) . AdFNGR and AdHNGR were produced and purified at titers comparable to Adwt presenting a wild-type capsid (data not shown). The presence of the NGR peptide coding sequence in the genome of both capsid-modified Ads was confirmed by PCR analyses and also by sequencing performed on DNA purified from viral particles (data not shown). In addition, SDS-PAGE analyses confirmed no differences in virus composition and integrity between NGR-bearing Ad and Adwt (data not shown). Then, we examined the ability of capsid-modified Ad to transduce CAR-overexpressing CHO cells (CHO-CAR). Measurement of b-galactosidase (b-gal) activity in cells infected with different MOI ranging from 10 2 to 10 4 vp per cell indicated similar levels of transduction for AdFNGR, AdHNGR and Adwt, thus showing that incorporation of NGR peptide did not impair transgene expression in CAR-expressing cells (Figure 1a ).
NGR peptide allows efficient endothelial cells transduction
As an isoform of CD13 (aminopeptidase N) expressed by endothelial cells was previously shown to interact with NGR peptide, 31 we examined the ability of AdFNGR and AdHNGR to transduce endothelial cells. First, we confirmed by FACS analyses the expression of CD13 by different endothelial cells (Table 2) . Transduction of EA.hy926, calf pulmonary artery endothelial cells (CPAE) and SLK infected with different MOI of Adwt, AdFNGR and AdHNGR was documented 1 day later by measurement of b-gal activity in cell lysates and by X-gal staining (Figures 1a and b) . AdFNGR triggered a twofold increase in b-gal activity, whereas AdHNGR led to a 40-fold increase in b-gal activity compared with Adwtinfected cells. We next assessed the ability of NGRbearing Ad to transduce HUVECs. AdFNGR induced b-gal activity comparable to that of Adwt, whereas AdHNGR led to an increase of up to 14-fold compared with Adwt ( Figure 1c) .
To analyze whether the increased expression of b-gal was linked to a better transduction of cells of endothelial origin by NGR-bearing Ad, we evaluated the amount of the Ad genome in EA.hy926-infected cells by using PCR. As expected, the amount of Ad genome increased with the MOI. Interestingly, higher levels of Ad genome were detected in cells infected with NGR-bearing Ad, with AdHNGR-infected cells displaying the highest level ( Figure 1d ). Altogether, these results indicated that NGR peptide provided Ad with a new entry pathway into endothelial cells.
NGR peptide allows efficient tumor cells transduction
To further characterize NGR-bearing Ad, we assessed their ability to transduce non-endothelial cells. Transduction of CD13-positive CAR-negative (Table 2) Table 2 ). However, blocking CAR receptors with recombinant Ad5 fiber knob revealed the ability of AdFNGR and AdHNGR to transduce HeLa cells better than Adwt in a CAR-independent way, most likely through the CD13 receptor (Figure 2b black columns and Table 2 ).
To confirm the CD13 specificity provided by capsid incorporation of NGR peptide, we examined the ability of NGR-bearing Ad to transduce CAR-and CD13-negative cell lines (Table 2) . Surprisingly, the fibroblast cell line L929 was efficiently transduced by AdFNGR and AdHNGR compared with Adwt. Also, the mammary tumor cell line MDA-MB-435S was efficiently transduced by AdHNGR (Figure 2c ). In contrast, the human mammary carcinoma MDA-MB-231 was not transduced more efficiently by NGR-bearing Ad than Adwt (data not shown).
Taken as a whole, our results indicated that NGR peptide provided Ad with a new entry pathway into CD13-positive tumoral cells, but also into some CD13-negative cells, thus suggesting the use of another receptor.
CD13 and avb3 integrins involvement in NGR-dependent cell entry
Results from our lab and others [31] [32] [33] suggested the existence of several receptors for NGR peptide. In a first attempt to define, which receptors are used by AdHNGR, we performed a virus overlay protein-binding assay using AdHNGR as a probe on total protein lysates of EA.hy926. Virus overlay protein-binding assay analyses showed three bands, the highest band corresponding to the CD13 migration pattern (data not shown).
To confirm CD13 involvement in NGR-dependent cell entry, we first performed competitions with pharmacological CD13 inhibitors. Pre-incubation with curcumin, an uncompetitive inhibitor, 34 was shown to block more than 85% of CD13 receptors (inset), leading to decreased b-gal expression in AdHNGR-infected Lewis lung carcinoma (LLC) (Figure 3a high SLK cells (black) were more efficiently transduced by AdHNGR than CD13 low SLK cells (gray). Finally, the role of CD13 was investigated using LLC cells infected with lentiviral vectors expressing either scramble shRNA or shRNA-targeting CD13. Although CD13 expression in LLC cells expressing CD13 shRNA was only slightly reduced (data not shown), these cells showed a reduced ability to be transduced by AdHNGR, as documented by b-gal expression (Figure 3d , right panel). Altogether, using three different methods, we confirmed the role of CD13 in Ad NGR-mediated entry pathway.
As integrins have also been proposed as alternative receptors for NGR peptide, 33 we analyzed their contribution to NGR-bearing Ad entry. To circumvent interactions between the RGD motif of the penton base with different integrins, we removed this motif from NGR-bearing Ad and Adwt, producing AdDRGD-HNGR, AdDRGD-FNGR and AdDRGD (Table 1 ). All DRGD-Ad bound to immobilized CAR. Whereas AdDRGD no longer bound to avb3 and avb5 integrins, AdDRGD-FNGR and AdDRGD-HNGR still retained the capacity to interact with avb3, but not with avb5 ( Figure 4a ). It should be noted that in contrast to AdDRGD and AdDRGD-FNGR, AdDRGD-HNGR slightly bound to a5b1 integrins. Co-incubation of antib3 antibody and AdDRGD-HNGR, with the CD13-negative and integrin b3-positive MDA-MB-435S cell line, reduced anti-b3 antibody binding more efficiently than AdDRGD (Figure 4b ). These results indicate that avb3 integrins could be another receptor for NGRbearing Ad. Increased angiostatic effects of NGR-bearing Ad-expressing K1-5
As NGR-bearing Ad were able to transduce endothelial cells more efficiently, we examined their ability to enhance production of anti-angiogenic molecules. Although all Ad except the empty control AdControl triggered comparable production of K1-5 in supernatants of CAR-expressing HeLa cells, K1-5 production by the endothelial CPAE cell line was enhanced with AdK1-5-FNGR and to a higher extent with AdK1-5-HNGR compared with AdK1-5 ( Figure 5a ). Higher production of K1-5 by AdK1-5-FNGR-and AdK1-5-HNGR-transduced EA.hy926 and CPAE cells led to a stronger decrease in cell survival compared with AdK1-5-and AdControl-transduced cells (Figure 5b ). This reduced cell survival was because of both increased cell death ( Figure 5c ) and reduced proliferation (Figure 5d ). It is noteworthy that in both cases, AdK1-5-HNGR showed a better efficacy than AdK1-5-FNGR. Altogether, these results indicated that NGR-bearing Ad are efficient tools to deliver anti-angiogenic factors into endothelial cells.
Inhibition of tumor growth by AdHNGR-encoding angiostatin K1-5
As NGR-bearing Ad transduce endothelial and tumor cells more efficiently in vitro, we sought to examine whether this could lead to improved gene delivery into tumors. To target tumor vessels, Adwt, AdFNGR and AdHNGR were injected intravenously into mice-bearing mammary carcinoma MDA-MB-231 xenografts. High b-gal activity was documented in liver lysates of Adwt-and AdFNGR-injected mice, but not in AdHGNR-injected mice (Supplementary Figure 1a-b) , as we previously observed for different hexon-modified Ads. 36 AdHNGR was shown to bind to immobilized blood factors FIX and FX, but was unable to use FX to Figure 1c-d) . In tumor lysates, low b-gal activity was measured with no difference between groups (data not shown), thus suggesting that Ad liver uptake precludes efficient targeting. As LLC (Figure 2a ) and MDA-MB-435S ( Figure 2b ) were efficiently transduced in vitro by AdFNGR and AdHNGR, we analyzed the ability of both viruses to transduce LLC-and MDA-MB-435S-derived tumors upon direct intratumoral injection. When all Ad-transduced LLC tumors are at the same level, AdHNGR was slightly better than Adwt at transducing MDA-MB-435S tumors, although this was not significant (data not shown). Therefore, as Ad interactions with its native receptors could have masked the NGR-dependent entry pathway, we pseudotyped AdHNGR with the Ad3 fiber as a first approach to de-targeting. This fiber is unable to interact with CAR and displays an affinity for CD46, 37 a receptor not expressed in mouse tissues except testis. AdF3 and AdF3-HNGR (Table 1) were able to transduce CD46-expressing cells (Figure 6a ) and AdF3-HNGR was able to transduce LLC cells more efficiently in vitro than AdF3 (Figure 6a ). Most interestingly, injection of AdF3-HNGR into LLC tumors pre-established in nude mice led to a threefold increase in b-gal expression (Figure 6b , Po0.01). Therefore, to examine the potency of this vector in an anti-angiogenic therapy, the lacZ transgene was replaced by angiostatin K1-5 cDNA. We observed from day 4 to day 14 (post infection) a significant (Po0.05) inhibition of LLC tumor growth following infection with AdK1-5-F3-HNGR compared with AdK1-5-F3 (Figure 6c) . Altogether, our data emphasize the potency of AdF3-HNGR to target and deliver therapeutic genes into tumors.
Discussion
Addressing different molecules to tumors in order to optimize drug delivery when limiting side effects is a major goal in the fight against cancer, but is also of crucial importance for increasing the efficacy of gene therapy vectors. This study showed that NGR peptide incorporation into Ad-capsid proteins allowed efficient transduction of endothelial as well as tumor cells. We also established that CD13 and avb3 integrins were involved in the entry of NGR-bearing Ad. Finally, we showed that such vectors are valuable tools for both in vitro and in vivo delivery of anti-angiogenic factors.
Two teams have previously shown that NGR peptide incorporation into fiber protein allowed Ad to more efficiently transduce rhabdomyosarcoma and glioblastoma cell lines. 24, 38 Majhen et al. used the CDCNGRCFC peptide whereas the second study used the same Virus overlay protein-binding assay analyses performed on EA.hy926 suggested interactions of AdHNGR with three potential receptors. As one of these interactions identified a protein with a migration pattern corresponding to CD13 MW, and because the NGR peptide showed a strong affinity for CD13, 31, 38 we assessed the role of this receptor in AdHNGR entry. First, cell transduction by AdHNGR increased with CD13 levels. Second, treatment of endothelial cells as well as tumor cells with pharmacological CD13 inhibitors reduced AdHNGR entry. Finally, AdHNGR entry was reduced in cells expressing shRNA-targeting CD13. These results confirmed the role of CD13 and pointed out that, contrary to previous published data, 31 NGR peptide is not specific to an endothelial-CD13 isoform.
NGR-bearing Ad were able to transduce CD13-negative cells, thus indicating the use of other receptors. Because NGR peptide is a mimetic of RGD peptide, 33 which is well-known to interact with different integrins, we examined the ability of NGR-bearing Ad to bind some of them. To circumvent native interactions of the penton-base with integrins, the RGD motif was deleted. We showed that, in contrast to AdDRGD, RGD-deleted NGR-bearing Ad were able to interact with avb3 integrins, but not with avb5. This observation is in accordance with a previous work showing that Ad in which fibers contain a CDCNGRCFC peptide interacted with avb3 integrins. 38 Recently, it was proposed that NGR peptide could be converted following a deamidation and subsequent hydroxylation into an isoDGR peptide able to interact with avb3 integrins. 39 Such a peptide modification may explain NGR-bearing Ad binding to avb3, but further studies are required to show unambiguously molecular basis of the binding of these vectors to CD13 and/or avb3. We also observed that AdDRGD-HNGR but not AdDRGD-FNGR bound weakly to a5b1. A binding to a5b1 integrin is not surprising according to the previous observation that NGR-bearing phages bind to this integrin. 32 The difference in binding to a5b1 between AdDRGD-HNGR and AdDRGD-FNGR may be linked to the number of motifs per capsid.
NGR-bearing Ad also efficiently transduced non-CD13, non-av and non-a5b1 integrins U118 glioblastoma (data not shown), thus suggesting the existence of another receptor. Further studies should help to identify this receptor and the exact sequence in NGR peptide involved in its binding. Altogether, the diversity of NGR receptors questioned the method-in vivo phage display in tumor-bearing mice-that allowed identification of this peptide. As tumor vasculature is leaky, phages could interact with endothelial cells, and also with tumor cells, fibroblasts and pericytes. 40 Our results showing interaction of NGR-bearing Ad with cells of different origin questions the high specificity of NGR peptide, and more precisely, the specificity of NGR peptide for CD13 expressed in endothelial cells in angiogenesis.
Although AdHNGR is able to efficiently transduce tumor and endothelial cells in vitro, its capacity to transduce tumors in vivo is far more difficult to assess. First, intravenous injection of AdHNGR results in a high liver uptake, thus reducing its blood half-life and its opportunity to interact with tumors. Second, as we observed for LLC cells (data not shown), a downmodulation of CD13 receptors on tumor cells could occur in vivo. Third, most AdHNGR could have interacted with Ad-native receptors in the tumor or its microenvironment, thus masking the interaction of NGR peptide with its receptors. This is reminiscent of what we observed in vitro upon infection of CARexpressing HeLa cells with AdHNGR. To assess the ability of NGR peptide to allow in vivo targeting, we pseudotyped AdHNGR by Ad3 fiber, which is unable to bind to CAR and heparan sulfate. 41 This could be considered as a first approach of de-targeting because the putative Ad3 fiber receptor, CD46, is not expressed in female mice. 37 Indeed, AdF3-HNGR triggered better transduction of LLC tumors than AdF3. The capability of AdK1-5-F3-HNGR to better transduce LLC tumors led to a strong reduction of the growth of this very aggressive tumor model. To the best of our knowledge, this is the first observation of a therapeutic effect after Ad-tumor targeting using NGR peptides. The ubiquitous expression of CD46 in humans prohibits the use of AdF3-HNGR for clinical treatment. However, control of Ad tropism could be achieved by mutating fiber 3 aminoacid residues involved in the interaction with CD46. Alternatively, hexon-NGR could be combined with other capsid modification, allowing efficient detargeting from Ad-native receptors.
Materials and methods
Ad vectors
LacZ-recombinant control Adwt (AE18 in Vigne et al 42 ) was derived from Ad5 with E1 and E3 regions deleted. AdDRGD and AdF3 were described previously as AE74 and DB6, respectively. 43 AdHNGR, AdDRGD-HNGR and AdF3-HNGR, derived from Adwt, AdDRGD and AdF3, respectively, contain a CNGRCVSGCAGRC peptide inserted into the hexon protein in place of T 269 TEAAAGNGDNLT 281 of hypervariable region 5. AdFNGR and AdDRGD-FNGR, derived from Adwt and AdDRGD, respectively, contain the same peptide inserted in place of T 539 QETGDTTPS 548 of the HI loop of the fiber protein. Angiostatin K1-5 7-9 recombinant Ad were derived from Adwt, AdF3, AdHNGR, AdFNGR and AdF3-HNGR by replacement of lacZ gene. All modified viruses (Table 1) were constructed using recombinational cloning in E. coli. 42 An Ad expressing no transgene (AdControl) served as a control of virus infection. 7 Virus production was performed in HEK293 or 633 cells, 44 kindly provided by Dr G Nemerow. Viruses
Targeted Ad-mediated gene delivery into tumors B Jullienne et al were obtained as described, 43 stored at -80 1C in PBS-7% glycerol and titrated by spectrophotometry (1 OD 260 ¼ 1.1 Â 10 12 vp/ml).
Production of lentivirus
pGIPZ plasmids recombinant for murine CD13 (RMM4431-99214006) or scramble (RHS4346) shRNA (Biovalley, Marne la Vallée, France) were used to produce lentiviral vectors as previously described. 45 Viral stocks were stored at À80 1C, and viral titers, expressed in transduction units (TU) ml
À1
, were determined by measurement of GFP-positive NIH 3T3 cells. Viral titers ranged from 1 to 5 Â 10 9 TU ml À1 . LLC cells were infected with the viral supernatant at a multiplicity of infection (MOI) of 10 TU and submitted to a 2-week selection with 10 mg ml À1 puromycine (Sigma, Lyon, France).
Cells
HUVECs (Clonetics, San Diego, CA, USA), CPAE, HEK293, HeLa, L929, LLC, MDA-MB-435S, RD and WEHI cells were maintained in media recommended by ATCC. CHO-CAR, 46 CHO-CD46, 47 and EA.hy926 endothelial hybridoma cells 48 
In vitro cell transduction
Confluent cell monolayers were infected with increasing MOI of different recombinant Ad in 400 ml of serum-free medium. After 1 h, 2 ml of complete medium was added.
In some experiments, cells were incubated for 30 min with 10 mg of recombinant fiber knob in serum-free medium before infection with Ad. In others, cells were either preincubated with curcumin (50 mM, Sigma) for 45 min at 37 1C in complete medium (10% FCS) before Ad infection, or incubated with 10 mg of PC-18 (PL350, Pharmaleads, Paris, France) and DTT (10 U) with Ad. Following a 1-h incubation with Ad, cells were washed with PBS and 2 ml of complete medium was added.
After 24 h, cells were lysed and b-galactosidase (b-gal) activity was measured using a chemiluminescent assay (BD Biosciences Clontech, Palo Alto, CA, USA) or assessed by X-Gal (5-bromo-4-chloro-3-indolyl-b-D-galactopyranoside) staining. Protein content was determined using the Bio-Rad Protein Assay (Bio-Rad Laboratories, Hercules, Marnes-la-Coquette, France). Results are expressed as relative light units per mg of protein.
Detection of adenoviral genome
Cells infected with different Ad were harvested after 24 h, DNA was extracted using DNAeasy Tissue Kit (Qiagen, Chatsworth, CA, USA) and DNA concentrations were determined by OD 260 1 mg) , integrin avb3, avb5 and a5b1 (2.5 mg, R&D Systems, Abingdon, UK) were immobilized onto a nitrocellulose membrane. After PBS-5% milk-0.05% IgePal (Sigma) blockage of free sites, the membrane, was incubated with 10 11 vp of different Ad in PBS-0.5% milk-0.05% IgePal, for 4 h at room temperature and processed as described previously. 36 
Western blot
Cells were infected for 4 h in serum-free medium with AdControl, AdK1-5, AdK1-5-FNGR or AdK1-5-HNGR at different MOI. Then, the medium was removed and serum-free medium was added. Supernatants were collected 72 h post-infection and remaining Ad heatinactivated. Supernatants were run into a NuPAGE (Novex, San Diego, CA, USA), transferred onto a nitrocellulose membrane, and probed with an antihuman angiostatin antibody (AF226, R&D Systems) followed by an HRP-conjugated anti-goat IgG (Jackson Immuno Research, West Groove, PA, USA).
Cell viability assays
Cells previously starved in serum-free medium for 24 h were mock-infected or infected with Ad at different MOI in serum-free medium, and complete medium was added 4 h later. After 96 h, cell viability was assessed by MTT assay (Sigma) and cell death by monitoring LDH release into the supernatant using the oxidation reaction of b-NADH in the presence of pyruvate (Sigma kit for LDH). The initial rate of absorbance decrease was measured in an automatic readout at OD 340 nm .
Cell proliferation assay
Cells (10 7 cell per ml) were incubated for 10 min at 37 1C in 10 mM 5-(and 6)-carboxyfluorescein diacetate succinimidylester (Molecular Probes, Eugene, OR, USA), washed with PBS, and plated. After 24 h, cells were mock-infected or infected with Ad at different MOI in serum-free medium and 3 h later complete medium was added. Cells were harvested after 72 h and the level of 5-(and 6)-carboxyfluorescein diacetate succinimidylester was measured by flow cytometry.
In vivo experiments
All animal experiments were approved by the IGR Institutional Animal Care and Use Committee. Athymic nu/nu female mice, 8 weeks old, from our animal facilities were injected subcutaneously with Lewis lung carcinoma (LLC, 2 Â 10 (50 ml) were injected intratumorally. Tumor growth was monitored twice each week for 2 weeks by measuring with calipers. For assessment of transgene expression, tumors were harvested 48 h later and snap frozen in liquid nitrogen. Transgene expression in tumor lysates was determined by measurement of bgal-activity as described. 43 Results are expressed as relative light units per microgram of protein.
Statistical analyses
A Mann-Whitney test, recommended for groups fewer than 30 mice, was conducted. Differences were considered significant when Po0.05.
